Can BRCA Mutation Cause Ovarian Cancer?

BRCA1 and BRCA2 mutations substantially increase the lifetime risk of ovarian cancer. A BRCA1 mutation carries an estimated risk of 35 to 70 percent, compared with 1 to 2 percent in the general population. BRCA2 mutations carry a somewhat lower but still significantly elevated risk. Both genes are responsible for repairing DNA damage, and a harmful mutation impairs that repair function, allowing cancer causing changes to accumulate over time. This risk can be substantially reduced through appropriate surgery.

According to Dr. Sandeep Nayak, Surgical Oncologist in India, “The scale of risk with a BRCA mutation surprises most patients when they first hear it. This is not a modest increase, it is a lifetime risk many times higher than the general population. BRCA1 and BRCA2 are genes responsible for repairing DNA damage, and when they carry a harmful mutation, that repair function fails. What matters clinically is that this risk, once identified, can be substantially reduced through appropriate surgery.”

The elevated risk from BRCA mutations is well documented and considerably higher than many expect.

• BRCA1 mutation : Carries a lifetime ovarian cancer risk of 35 to 70 percent. That figure alone runs dozens of times higher than the general population.
• BRCA2 mutation : Sits somewhat lower than BRCA1, though the risk still climbs well past baseline, which shapes how surveillance and surgery are timed.
• DNA repair genes : Both genes normally fix damaged DNA. A harmful mutation breaks that repair machinery, letting errors build up quietly over years.
• Breast cancer risk too : Both mutations raise breast cancer risk alongside ovarian cancer, which is why genetic counselling weighs the two together, not one in isolation.

Understanding this risk is central to informed ovarian cancer treatment planning for women with a known mutation or relevant family history.

For confirmed BRCA carriers, several evidence based options exist to manage this elevated risk.

• Genetic testing : Recommended for anyone with a family history of ovarian or breast cancer, particularly cancer diagnosed at a younger age in close relatives.
• Risk reducing surgery : Removing the ovaries and fallopian tubes once childbearing is complete cuts ovarian cancer risk by roughly 80 to 90 percent.
• Timing by mutation : Surgery is generally recommended earlier for BRCA1 carriers than for BRCA2 carriers, since the risk climbs sooner in BRCA1.
• Interim surveillance : For those not yet ready for surgery, closer monitoring offers a bridge while family planning decisions are still being made.

This surgical option is part of the broader approach discussed in ovarian cancer surveillance, particularly relevant for women at elevated genetic risk.

Dr. Sandeep Nayak is a surgical oncologist with 24 years of experience and a fellowship in laparoscopic and robotic onco-surgery. For women carrying a BRCA mutation, his approach involves coordinating genetic counselling alongside the surgical decision, and weighing the timing against family planning rather than applying a single fixed rule to everyone. Identified genetic risk becomes something to act on, not simply something to monitor indefinitely.

A BRCA mutation raises the odds considerably. It does not make ovarian cancer certain. Testing establishes where a woman stands, and for those who carry the mutation, risk reducing surgery brings the odds back down meaningfully. Getting the sequence right, testing, counselling, then timing surgery to the individual, is what turns a significant risk figure into something manageable.

References

1. BRCA1 and BRCA2 associated ovarian cancer risk — National Library of Medicine
2. Risk reducing salpingo-oophorectomy outcomes — National Library of Medicine

Disclaimer: This blog is for informational and educational purposes only and is not a substitute for professional medical advice or diagnosis.